NuPathe dumps Endo

Share this article:

Teva has swept in and upset Endo's NuPathe merger. Endo issued a statement Monday that NuPathe rejected Endo's bid, which meant coughing up a $5-million termination fee in order to go forward with Teva.

Specialty pharmaceutical company Endo offered $104 million for the company, but Business Week says Teva topped this by offering $144 million.

The deal means NuPathe's Zecuity migraine patch will now belong to Teva.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.